Clinical Guidelines

AUGMENT-101 Trial: Menin Inhibitor Revumenib Shows Activity in <em>KMT2A</em>-Rearranged Acute Leukemia

In heavily pretreated patients with a challenging type of acute leukemia, the menin inhibitor revumenib demonstrated clinically meaningful activity, including high rates of response and measurable res...

Share

Dr. Ibrahim Aldoss presented efficacy and safety results of the phase II AUGMENT-101 trial at the 2023 ASH Annual Meeting & Exposition. The trial evaluated the menin inhibitor revumenib in heavily pretreated patients with relapsed or refractory KMT2A-rearranged acute leukemia. The drug demonstrated clinically meaningful activity, with high rates of response and measurable residual disease negativity. KMT2A-rearranged leukemia, representing about 10% of all acute leukemias, has a poor prognosis, and there is currently no approved treatment targeting the menin-KMT2A interaction. Revumenib holds promise in this area and in NPM1-mutated leukemia. The safety profile of revumenib was encouraging, with manageable toxicities. The study was significant as it provided insights into a novel treatment approach for a challenging type of leukemia.

Original Source(s)

AUGMENT-101 Trial: Menin Inhibitor Revumenib Shows Activity in <em>KMT2A</em>-Rearranged Acute Leukemia

  • by Caroline Helwick

  • February 16, 2024

Related Content

Enhancing Immune Thrombocytopenia Education and Support: Insights From a Learning Exchange Program

AML Complexity Uncovered: A Unified Whole Genome and Informatics Approach for High Resolution Disease Understanding

Standard-of-care (SOC) genomic testing in acute myeloid leukemia (AML) has historically resulted in fragmented, incomplete genomic profiles that mask clinically significant biology.

  • March 12, 2026

GIMEMA ALL2820: Chemotherapy-Free Regimen Studied in Front-Line Setting

As front-line therapy, a chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed standard treatment ...